After an outstanding track record of 5 Star Stocks, I am excited to announce our new 5 Star Stock HepaLife Technologies Inc. trading under ticker symbol HPLF.OB currently at only $0.26! For all of our new club members our 5 Star ranking is our highest level of confidence in a new pick!

HPLF's upside potential is astronomical. The last time HPLF made a run it had one of the most unbelievable runs I have ever seen in the small cap arena. Take a look at this chart below to see what I'm talking about. As you can see HPLF ran from as low as $0.05 to as high as $5.80 for a whopping 11,500% gain! Have you ever seen anything like this before!?

I think the chart looks great now and the stock is completely cleaned up at this point. In my opinion, HPLF is getting ready to make its next spectacular run soon and you should not miss out on this one. I don't know exactly when this could happen but all I know is that it will happen sooner or later, in my opinion. If it starts to run too much too quick and gaps up since it has such a low float then I would sit back and wait for a dip to get a reasonable price point around the $0.30 price point. Anything under $0.30 is an absolute gift. Please take your time researching HPLF and keep an eye out for updates from the company in the future.

The World Health Organization estimates that over 650 million people worldwide are affected by some form of liver disease. In the US alone, there are around 500,000 critical episodes of liver problems requiring hospitalization with 80,000 deaths annually. Liver transplantation is currently the only therapy proven to extend survival, but the waiting list for liver transplants is extensive and many on the list will not receive an organ. Additionally, a growing base of hepatitis, alcohol abuse, drug overdoses, liver cancer and other factors all clearly indicate a strong need for a bioartificial liver support system.

HPLF is developing its cell-based bioartificial liver system, HepaMate, as a potentially lifesaving treatment for liver failure patients! The patented technology has previously been tested in clinical Phase I and pivotal Phase II/III studies involving more than 200 patients, making it the most clinically studied bioartificial liver. Over 50 scientific papers and book chapters have been published on the technology. HPLF expects a new pivotal Phase III clinical trial to be successful in obtaining market approval for its HepaMate bioartificial liver system.

There are currently no cell-based liver support systems commercially available or in advanced Phase III clinical trials in the USA or Europe. This makes HPLF a truely unique investment opportunity of a lifetime.

As an extracorporeal cell-based bioartificial liver system, HepaMate is designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. A patented liver cell cryopreservation process provides for safe and easy storing and distribution, a significant logistic and commercial advantage.

Click here if you want to see how HepaMate  works-  

HPLF is currently in a great position at $0.26 with a market cap of only $23.9 million. The company's last private placement was in May of 2008 for $4,530,800 at $0.425 per share. This obviously shows how much of a value the stock is at the current PPS compared to the PPM that was done. Furthermore, HPLF has $2.36 million in cash and NO DEBT!

I believe HPLF could become one of our biggest winners of all-time one day. Make sure to do your due diligence. 

If you have questions or comments please give us a call during market hours at 1-(888)-925-8247. Please Help spread the Word!!

MORE UPDATES TO COME...

If you have any questions feel free to email me or call us at 1-(888)-9-Club Grand -or- staff@wallstreetgrand.com

Wall Street Grand's stock profiles are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. Never invest into a stock we discuss unless you are prepared to lose your entire investment. WSG has not been compensated for the profile of HPLF but does have a relationship with large shareholders of the company that have retained WSG for investor relation services in the past and may compensate WSG in the future for future business. We may be compensated to profile HPLF in the future but we have not come to any agreements at this time. You may consider our profile of HPLF to be biased. WSG may have positions in the stocks mentioned above. WSG may or may not trade the stocks mentioned in this alert which can effect the price of the stock. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country Everything stated in WSG alerts are based on my opinion. For our full disclosure please visit- http://www.wallstreetgrand.com/disclosure.html